The Center and its core facilities have been instrumental in developing public and private partnerships and have played a key role developing and submitting to federal agencies cross-disciplinary grant applications for research on nanomedicine technologies including successful renewal of the Carolina Center of Cancer Nanotechnology Excellence (CCNE) and establishment of the Carolina Cancer Nanotechnology Training Program (C-CNTP).


Kristy Ainslie, Ph.D.

  1. Microparticle resiquimod for the treatment of visceral leishmaniasis
    5R21AI123692-02
    NIAID, 04/15/2016 – 03/31/2019; Role: PI
  2. Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
    5R01AI125147-02
    NIAID, 04/22/2016 – 03/31/2021; Role: PI
  3. Nanofiber matrices to improve neural stem cell-mediated cancer therapy
    5R01NS097507-02
    NINDS, 06/01/2016 – 05/31/2021; Role: Co-Investigator
  4. Advancing Formulation of Sting Agonist For Universal Flu Vaccine
    1R41AI140795-01
    NIAID, Immvention Therapeutix, Inc., 06/01/2018 – 10/31/2019; Role: PI
  5. Biomaterials to Study Tolerance Immune Induction Kinetics
    1R01AI137525-01A1
    NIAID, 08/14/2018 – 07/31/2023; Role: PI

Eric Michael Bachelder, Ph.D.

  1. Microparticle resiquimod for the treatment of visceral leishmaniasis
    5R21AI123692-02 Proj ID 5104141
    NIAID, 04/15/2016 – 03/31/2019; Role: Co-Investigator
  2. Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
    5R01AI125147-02
    NIAID, 04/22/2016 – 03/31/2021; Role: Co-Investigator
  3. Nanofiber matrices to improve neural stem cell-mediated cancer therapy
    5R01NS097507-02
    NINDS, 06/01/2016 – 05/31/2021; Role: Co-Investigator
  4. Advancing Formulation of Sting Agonist For Universal Flu Vaccine
    1R41AI140795-01
    NIAID, Immvention Therapeutix, Inc., 06/01/2018 – 10/31/2019; Role: Co-Investigator
  5. Biomaterials to Study Tolerance Immune Induction Kinetics
    1R01AI137525-01A1
    NIAID, 08/14/2018 – 07/31/2023; Role: Co-Investigator

Edward Moreira Bahnson, Ph.D.

  1. Cell-Mediated Targeted Redox Intervention for the Prevention of Restenosis in the Injured Vasculature
    CTSA KL2, 05/01/2017—04/30/2020; Role: PI
  2. Molecular Imaging of Atherosclerosis in Mutant ApoE Deficient Rats
    Burroughs Wellcome Fund, 06/01/2018—12/31/2019; Role: PI

Elena Batrakova, Ph.D

  1. Cell-Based Platform for Gene Delivery to the Brain
    1R01NS102412-01A1
    NINDS, 03/01/2018 – 11/30/2022; Role: PI
  2. Developing Exosome-based Delivery of TPP1 for Batten Disease Therapy
    Eshelman Institute for Innovation, 2018; Role: PI

Soumya Benhabbour, Ph.D.

  1. Development and Pre-Clinical Evaluation of a Novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEP
    5R01AI131430-02
    NIAID, 03/06/2017 – 02/29/2020; Role: PI
  2. Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose Intravaginal Rings for Prevention of HIV, STIs and Unintended Pregnancy
    1R61AI136002-01
    NIAID, 08/08/2018 – 07/31/2020; Role: PI

Yevgeny Brudno, Ph.D.

  1. Biomaterial-Assisted In Situ Generation of CAR-T Cells
    Flash Grant
    North Carolina Biotechnology Center, 04/2019-12/2019; Role: PI
  2. Refillable Therapeutic Depots for Treatment of Brain Disease
    Junior Faculty Development Award
    UNC, 01/2019-01/2020; Role: PI
  3. Evaluation of next-generation adjuvants for development of a canine cancer vaccine
    Intramural Grant
    College of Veterinary Medicine, NC State, 06/2018-05/2019; Role: Co-PI
  4. Local Immunotherapy Made Possible by Click-Enabled Refillable Therapeutic Depots
    Faculty Research and Professional Development Program
    NC State, 09/2018-09/2019; Role: PI
  5. Targeting Glioblastoma Recurrence Through Hyperosmosis-Enabled Refillable Drug Depots
    Developmental Grants
    UNC Lineberger, 03/2018-03/2019; Role: PI
  6. Targeting Glioblastoma Recurrence Through Focused Ultrasound-Enabled Refillable Drug Depots
    5-50K Grant
    NCTraCS, 01/2018-01/2019; Role: PI

Paul Dayton, M.D.

  1. Quantitative Ultrasound Analysis Of Vascular Morphology For Cancer Assessment
    5R44CA165621-04
    NCI, Kitware, Inc., 09/01/2012 – 06/30/2019; Role: PI
  2. Ultrasound Molecular Imaging To Assess Therapeutic Response
    5R01CA195051-04
    NCI, University of Colorado, 04/13/2015 – 03/31/2019; Role: PI
  3. The Application of Enhanced Cavitation to Enable DNA and Chromatin Extraction from Archived Tissues
    1R33CA206939-01A1
    NCI, 07/01/2017 – 06/30/2020; Role: PI
  4. High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging
    1R01CA220681-01
    NCI, 08/10/2017 – 07/31/2022; Role: PI
  5. An Academic Industrial Partnership for the Development of High Frame-Rate Transcranial Super Resolution Ultrasound Imaging
    1R01EB025149-01
    NIBIB, 09/30/2017 – 07/31/2019; Role: PI
  6. Treating Tumoral Hypoxia Via Ultrasound-Guided Oxygen Release For Improving Radiation Therapy
    1R01CA232148-01
    NCI, 06/01/2018 – 05/31/2023; Role PI
  7. Acoustic Angiography Using Dual-Frequency And Ultrawideband CMUT Arrays
    1R01EB026897-01
    NIBIB, NC State University, 07/01/2018 – 03/31/2022; Role: PI
  8. Towards Commercialization Of Cavitation-Enhancing Nanodroplets For DNA Sample Fragmentation In NGS Applications
    1R43CA232902-01
    NCI, Triangle Biotechnology, Inc., 07/05/2018 – 06/20/2019; Role: PI

Zongchao Han, M.D., Ph.D.

  1. Targeting Retinitis Pigmentosa Using Nanoparticle-Mediated Delivery of Genomic DNA
    1R01EY026564-01
    NEI, 04/01/2016 – 03/31/2021; Role: PI

Shawn D. Hingtgen, Ph.D.

  1. Nanofiber matrices to improve neural stem cell-mediated cancer therapy
    5R01NS097507-02
    NINDS, 06/01/2016 – 05/31/2021; Role: PI
  2. 3D Printing of Fibrous Tissue Engineered Medical Products: A New Paradigm for Tissue Biofabrication and Therapeutics
    NCSU GRIP, 02/01/2017 – 1/31/2020; Role: PI
  3. STTR: Personalized Neural Stem Cell Therapy for Cancer
    1R41TR001789-01A1
    NCATS, Falcon Therapeutics Inc., 06/15/2017 – 06/14/2019; Role: Co-Investigator
  4. Engineering stem cell therapies to understand and overcome glioblastoma adaption
    1R01NS099368-01A1
    NINDS, 09/26/2017 – 06/30/2022; Role: PI
  5. Native and Bioprinted 3D Tissue Array Platform for Predicting Cancer Metastasis and Drug Response
    Eshelman Institute for Innovation, 2018; Role: PI

 Leaf Huang, Ph.D.

  1. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    1U54CA198999-01
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  2. Developmental Program
    1U54CA198999-01
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  3. Administrative Core
    1U54CA198999-01
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  4. Project 1: Nanotherapies for Vemurafenib Resistant Melanoma
    1U54CA198999-01
    NCI, 09/01/2015 – 07/31/2020; Role: PI

Michael Jay, Ph.D.

  1. An Optimized NK2R Agonist for ‘On-Demand’ Voiding
    2R44AG055169-02
    NIA, Dignify Therapeutics, Inc., 09/30/2016 – 05/31/2019
  2. The Osmopatch: An Osmotic Controlled-Release Transdermal Drug Delivery System
    Eshelman Institute for Innovation, 2018; Role: PI

Alexander Kabanov, Ph.D., Dr. Sci.

  1. PEGylated Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
    5R01CA184088-04
    NCI, 1/01/2015 – 12/31/2019; Role: PI
  2. Carolina Cancer Nanotechnology Training Program (C-CNTP)
    5T32CA196589-03
    NCI, 7/01/2015 – 6/30/2020; Role: Director
  3. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    5U01CA198910-03
    NCI, 8/14/2015- 7/31/2020; Role: PI
  4. Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
    5U54CA198999-03
    NCI, 9/01/2015 – 7/31/2020; Role: PI
  5. Targeted Magneto-Mechanic Nanotherapeutics for Cancer
    1R21CA220148-01
    NCI, 8/1/2017 – 7/31/2020; Role: PI
  6. Systemic Targeting of Mononuclear Phagocytes for Parkinson’s Disease Gene Therapy
    Eshelman Institute for Innovation, 2017; Role: PI
  7. Nanoparticle Delivery of Cas9 and Therapeutic gRNAs to the Brain
    Eshelman Institute for Innovation, 2018; Role: PI
  8. Brain Drug Delivery: Optimizing miR-29 Nanoformulation for Neuroprotection
    Eshelman Institute for Innovation, 2018; Role: PI

Melina Kibbe, M.D.

  1. Development of a Targeted Intravascular Therapy to Stop Non-Compressible Torso Hemorrhage
    Air Force Research Laboratory, University of Cincinnati, 10/24/2016—10/23/2019; Role: PI
  2. Targeted, Niche-Responsive Peptide Amphiphile Nanofibers as Injectable Drug Delivery Vehicles to Treat Atherosclerosis
    American Heart Association, 07/01/2018—06/30/2020; Role: PI

Sam Lai, Ph.D.

  1. Artificial Neural Networks for High Performance, Fully Automated Particle Tracking Analysis Even at Low Signal-to-Noise Regimes
    1R41GM123897-01
    NIGMS, AI Tracking Solutions, 05/01/2017 – 04/30/2019; Role: PI
  2. Enhancing AAV gene therapy via bispecific fusion proteins that block anti-AAV antibodies while conferring active targeting
    NCBC, 11/01/2017 – 10/31/2019; Role: PI
  3. Overcoming Anti-PEG Immunity To Restore Prolonged Circulation And Efficacy Of PEGylated Therapeutics
    1R01HL141934-01
    NHLBI, 05/10/2018 – 04/30/2022; Role: PI
  4. In Vivo Engineering of T-cells for CAR-T-based Therapy
    Eshelman Institute for Innovation, 2018; Role: PI

Rihe Liu, Ph.D.

  1. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    1U01CA198910-01
    NCI, 08/14/2015 – 07/31/2020; Role: PI
  2. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    1U54CA198999-01
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  3. Inhibition Of GTPases and G Proteins to Treat Human Disease
    5R01GM120291-03
    NIGMS, 09/15/2016 – 07/31/2020; Role: PI
  4. Nanoscintillator-based X-ray sensitizers to enable efficient non-small cell lung cancer treatment with X-ray irradiation
    5R01EB022596-02
    NIBIB, University of Georgia, 03/15/2017 – 01/31/2021; Role: Co-Investigator
  5. A Wholly Protein-based Self-assembly Nanoplatform for Tunable Cancer Immunotherapy
    Eshelman Institute for Innovation, 2018; Role: PI

Chad Pecot, M.D.

  1. Tumor Angiogenesis Regulation by the miR-200 Family
    MRSG-14-222-01
    American Cancer Society, 01/01/2015 –12/31/2019; Role: PI
  2. Targeting Lung Squamous Metastasis with CCR2 Inhibitors
    Free to Breath, 02/14/2017 – 12/31/2019; Role: PI
  3. HDAC11 Promotes Breast Cancer Metastasis via the Lymphatic Route
    Susan G. Komen for the Cure; 08/07/2017 – 08/06/2020; Role: PI
  4. Immune Regulation Of Lung Squamous Metastasis
    1R01CA215075-01A1
    NCI, 09/21/2017 – 08/31/2022; Role: PI

Marina Sokolsky, Ph.D.

  1. Targeted Magneto-Mechanic Nanotherapeutics for Cancer
    1R21CA220148-01
    NCI, 8/1/2017 – 7/31/2020; Role: Co-Investigator
  2. BCL-xL-regulated Apoptosis in Cerebellar Development and Medulloblastoma Treatment
    1R01NS102627-01A1
    NINDS, 06/01/2018 – 04/30/2023; Role: Co-Investigator
  3. Treating medulloblastoma with nano-formulated SHH and CDK4/6 inhibitors
    St. Baldrick’s Foundation, 07/01/2018 – 06/30/2019; Role: PI

Alexander Tropsha, Ph.D.

  1. Nano Approaches to Modulate Host Cell Response for Cancer Therapy
    1U54CA198999-01
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  2. Materials Informatics Platform for Property Prediction
    N00014-16-1-2311
    DOD, 02/04/2016 – 05/31/2019; Role: PI
  3. Integrating cheminformatics and molecular simulations for virtual drug screening
    5-R01-GM114015-01
    NIGMS, 08/15/2016 – 05/31/2020; Role: Co-Investigator
  4. Drug Repurposing for Cancer Therapy: From Man to Molecules to Man
    5-U01-CA207160-03
    NCI, 09/01/2016 – 08/31/2019; Role: PI
  5. Carolina Biomedical Data Translator Technical Feasibility Assessment and Architecture Design
    1OT3TR002020-01
    NCATS, 09/24/2016 – 12/31/2019; Role: PI
  6. Chemoenzymatic Synthesis, Mode of Action and Evolution of Natural Product-based Macrocycles
    1-R35-GM125005-01
    NIGMS, 09/05/2017 – 08/31/2022; Role: Co-Investigator
  7. Dual mechanism thiopeptide analogs for TB drug development
    1-R21-AI138058-01
    NIAID, 05/10/2018 – 04/30/2020; Role: Co-Investigator
  8. Drug repurposing for Alzheimer’s disease using both observational and chemical genomics data
    1-R56-AG059428-01
    NIA, 08/15/2018 – 07/31/2019; Role: PI

Nick Tsihlis, Ph.D.

  1. Development of a Targeted Intravascular Therapy to Stop Non-Compressible Torso Hemorrhage
    Air Force Research Laboratory, University of Cincinnati, 10/24/2016—10/23/2019; Role: Co-Investigator

Andrew Wang, M.D.

  1. Carolina Cancer Nanotechnology Training Program (C-CNTP)
    5T32CA196589-03
    NCI, 7/01/2015 – 6/30/2020; Role: Co-Director
  2. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    5U01CA198910-03
    NCI, 08/14/2015 – 07/31/2020; Role: Co-Investigator
  3. Project 3: Combining Radiotherapy and Nanotechnology for Immunotherapy
    1U54CA198999-0
    NCI, 09/01/2015 – 07/31/2020; Role: PI
  4. Automatic Pelvic Organ Delineation in Prostate Cancer Treatment
    5R01CA206100-02
    NCI, 09/01/2016 – 07/31/2021; Role: Co-Investigator
  5. Nanoscintillator-based X-ray sensitizers to enable efficient non-small cell lung cancer treatment with X-ray irradiation
    5R01EB022596-02
    NIBIB, University of Georgia, 03/15/2017 – 01/31/2021; Role: Co-Investigator

William Zamboni, Pharm.D., Ph.D.

  1. Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
    5UM1CA186704-04
    NCI, Duke University, 04/04/2014 – 02/29/2020; Role: Co-Investigator
  2. Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy
    5R01CA184088-04
    NCI, 01/01/2015 – 12/31/2019; Role: PI
  3. Targeted Core Shell Nanogels for Triple Negative Breast Cancer
    5U01CA198910-03
    NCI, 08/14/2015 – 07/31/2020; Role: Co-Investigator
  4. Project 4: High Capacity Polymeric Micelle Therapeutics for Lung Cancer
    5U54CA198999-03
    NCI, 09/01/2015 – 07/31/2020; Role: Co-Investigator
  5. Overcoming Anti-PEG Immunity to Restore Prolonged Circulation and Efficacy of PEGylated Therapeutics
    1R01HL141934-01
    NHLBI, 05/10/2018 – 04/30/2022; Role: PI